Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
Frits S.A.M. van Dam(The Netherlands Cancer Institute), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Elsken van der Wall(University Medical Center Utrecht), Sanne B. Schagen(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Martin Müller(The Netherlands Cancer Institute), Maria E. Droogleever Fortuyn(The Netherlands Cancer Institute), Willem Boogerd(The Netherlands Cancer Institute)
Cited by 768
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
|New England Journal of Medicine|1990|811
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
|JNCI Journal of the National Cancer Institute|2001|593
The Amsterdam Preoperative Anxiety and Information Scale (APAIS)
|Anesthesia & Analgesia|1996|544
Mutational Activation of the K-<i>ras</i>Oncogene
|New England Journal of Medicine|1987|540